- Previous Close
0.3051 - Open
0.2959 - Bid --
- Ask --
- Day's Range
0.2901 - 0.3126 - 52 Week Range
0.2800 - 4.7900 - Volume
516,025 - Avg. Volume
2,606,031 - Market Cap (intraday)
11.969M - Beta (5Y Monthly) 0.34
- PE Ratio (TTM)
-- - EPS (TTM)
-1.8100 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
www.leaptx.comRecent News: LPTX
View MorePerformance Overview: LPTX
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LPTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LPTX
View MoreValuation Measures
Market Cap
12.58M
Enterprise Value
-34.40M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.36
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-71.81%
Return on Equity (ttm)
-142.43%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-68.02M
Diluted EPS (ttm)
-1.8100
Balance Sheet and Cash Flow
Total Cash (mrq)
47.25M
Total Debt/Equity (mrq)
0.76%
Levered Free Cash Flow (ttm)
-36.72M